SAN DIEGO, Aug. 23, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil will host the Third Meeting of Former Residents of Neurology at John Paul II Children’s Hospital in Belo Horizonte, Minas Gerais, Brazil on Aug. 25.
“We are looking forward to having a discussion on the benefits of cannabis and expanded access to CBD in Brazil,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We want to support CBD access around the world and further develop our ongoing relationship with Brazilian healthcare professionals.”
During the event, Dr. Titus will present on CBD and its benefits. The event will also include a lineup of reputable speakers including Director of Medical Affairs at HempMeds® Brazil Dr. Sergio Gibelli Junior and Dr. Rubens Wajnszejn.
“Our Company is excited to host such an influential event bringing doctors of neurology together to discuss the benefits of CBD,” said HempMeds® Brasil Vice President Caroline Heinz. “We hope that the event will present itself as an opportunity for doctors to help us create and facilitate a culture of education and acceptance surrounding CBD in Brazil.”
To learn more about the event, please visit https://hempmeds.com.br/.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications. www.hempmeds.com.br.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer CMW Media